Literature DB >> 19118524

Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists.

Songwen Zhang1, Qiangyuan Liu, Juan Wang, Douglas C Harnish.   

Abstract

C-reactive protein (CRP), a human acute-phase protein, is a risk factor for future cardiovascular events and exerts direct pro-inflammatory and pro-atherogenic properties. The farnesoid X receptor (FXR), a member of the nuclear hormone receptor superfamily, plays an essential role in the regulation of enterohepatic circulation and lipid homeostasis. In this study, we report that two synthetic FXR agonists, WAY-362450 and GW4064, suppressed interleukin-6-induced CRP expression in human Hep3B hepatoma cells. Knockdown of FXR by short interfering RNA attenuated the inhibitory effect of the FXR agonists and also increased the ability of interleukin-6 to induce CRP production. Furthermore, treatment of wild type C57BL/6 mice with the FXR agonist, WAY-362450, attenuated lipopolysaccharide-induced serum amyloid P component and serum amyloid A3 mRNA levels in the liver, whereas no effect was observed in FXR knockout mice. These data provide new evidence for direct anti-inflammatory properties of FXR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19118524     DOI: 10.1016/j.bbrc.2008.12.117

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  FXR deletion in hepatocytes does not affect the severity of alcoholic liver disease in mice.

Authors:  Min Zhang; Bo Kong; Mingxing Huang; Ruixuan Wan; Laura E Armstrong; Justin D Schumacher; Daniel Rizzolo; Monica D Chow; Yi-Horng Lee; Grace L Guo
Journal:  Dig Liver Dis       Date:  2018-04-23       Impact factor: 4.088

2.  Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.

Authors:  Justin D Schumacher; Bo Kong; Jason Wu; Daniel Rizzolo; Laura E Armstrong; Monica D Chow; Michael Goedken; Yi-Horng Lee; Grace L Guo
Journal:  Hepatology       Date:  2019-08-09       Impact factor: 17.425

Review 3.  Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Justin D Schumacher; Grace L Guo
Journal:  Handb Exp Pharmacol       Date:  2019

Review 4.  Stress as an immunomodulator: liver X receptors maybe the answer.

Authors:  Issam Nessaibia; Allan Fouache; Jean-Marc A Lobaccaro; Abdelkrim Tahraoui; Amalia Trousson; Maâmar Souidi
Journal:  Inflammopharmacology       Date:  2018-11-22       Impact factor: 4.473

5.  Cholestasis-induced bile acid elevates estrogen level via farnesoid X receptor-mediated suppression of the estrogen sulfotransferase SULT1E1.

Authors:  Xijun Liu; Ruyi Xue; Caiting Yang; Jianxin Gu; She Chen; Si Zhang
Journal:  J Biol Chem       Date:  2018-06-21       Impact factor: 5.157

Review 6.  Role of farnesoid X receptor in inflammation and resolution.

Authors:  Firdose Begum Shaik; Durbaka V R Prasad; Venkata Ramireddy Narala
Journal:  Inflamm Res       Date:  2014-11-07       Impact factor: 4.575

Review 7.  Obesity, cardiovascular disease, and role of vitamin C on inflammation: a review of facts and underlying mechanisms.

Authors:  Mohammed S Ellulu
Journal:  Inflammopharmacology       Date:  2017-02-06       Impact factor: 4.473

Review 8.  Role of fish oil in human health and possible mechanism to reduce the inflammation.

Authors:  Mohammed S Ellulu; Huzwah Khaza'ai; Yehia Abed; Asmah Rahmat; Patimah Ismail; Yazan Ranneh
Journal:  Inflammopharmacology       Date:  2015-02-14       Impact factor: 4.473

9.  Mechanisms of STAT3 activation in the liver of FXR knockout mice.

Authors:  Guodong Li; Yan Zhu; Ossama Tawfik; Bo Kong; Jessica A Williams; Le Zhan; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-03       Impact factor: 4.052

10.  Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis.

Authors:  Laura E Armstrong; Grace L Guo
Journal:  Curr Pharmacol Rep       Date:  2017-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.